DELCATH SYSTEMS, INC.
Delcath Systems, Inc. (Nasdaq: DCTH) is an interventional oncology company focused on developing and commercializing treatments for cancers primary or metastatic to the liver. The company's website is www.delcath.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What DELCATH SYSTEMS, INC. does
In the company’s own words
Delcath Systems, Inc. (Nasdaq: DCTH) is an interventional oncology company focused on developing and commercializing treatments for cancers primary or metastatic to the liver. The company's website is www.delcath.com.
The company's lead product is HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), a drug-device combination product approved by the FDA in August 2023 for treating adult patients with uveal melanoma with unresectable hepatic metastases. HEPZATO represents a liver-directed therapy designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a percutaneous hepatic perfusion procedure. The first commercial use of HEPZATO occurred in January 2024, with 25 active treatment sites as of December 31, 2025.
In Europe, Delcath markets CHEMOSAT Hepatic Delivery System for Melphalan, a device-only configuration approved under the European Medical Devices Regulation. CHEMOSAT has been used at major medical centers across 22 cancer centers in Europe, with over 2,000 commercial treatments conducted since launch. As of March 1, 2022, the company assumed direct responsibility for sales, marketing, and distribution of CHEMOSAT in Europe.
The company operates as a single operating segment and has obtained six orphan drug designations for various liver cancer indications including uveal melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumors. Beyond its approved indication, Delcath is conducting clinical development programs to evaluate HEPZATO for treating additional liver cancers including metastatic colorectal cancer, metastatic breast cancer, and hepatocellular carcinoma.
Delcath has secured regulatory support including a permanent J-Code from the Centers for Medicare and Medicaid Services, transitional drug pass-through status for hospital outpatient services, and New Technology Add-on Payment status under the inpatient prospective payment system. The company entered into a National Drug Rebate Agreement with CMS in October 2025, subjecting it to Medicaid rebates and 340B pricing requirements. The addressable market for liver cancer treatments is estimated at over one billion dollars annually across multiple indications in the United States and Europe.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- QUEENSBURY, NY
- Fiscal year end
- December
- CIK
- 872912
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns DELCATH SYSTEMS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · DELCATH SYSTEMS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do DELCATH SYSTEMS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of DELCATH SYSTEMS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in DELCATH SYSTEMS, INC.'s last four quarterly filings that the numbers alone won't show?”